¤½§i¥»¤½¥q108¦~ªÑªF±`·|³q¹L¸Ñ°£¤½¥qªk²Ä209±ø¦³Ãö¸³¨ÆÄv·~¸T¤î¤§¨î®×
1.ªÑªF·|¨Mij¤é:108/06/24
2.³\¥i±q¨ÆÄv·~¦æ¬°¤§¸³¨Æ©m¦W¤Î¾ºÙ:
(1)¸³¨Æ:±ä¥Å
(2)¸³¨Æ:¤é°Ó¹q¤Æ®è¦¡·|ªÀ¥Nªí¤H:¤j¾ô«O§»
(3)¸³¨Æ:DPT Biofund LLC¥Nªí¤H¡GCarolyn Tsao
(4)¸³¨Æ:Âļ¯¨È°ÓConcorde International Corporation¥Nªí¤H¡G
Stuart Michael Palmer
(5)¿W¥ß¸³¨Æ:±ä¼w·
(6)¿W¥ß¸³¨Æ:§E°ê¨}
3.³\¥i±q¨ÆÄv·~¦æ¬°¤§¶µ¥Ø:
±ä¥Å¥Ø«eÝ¥ô:
1.CMC Pharma Solutions Group Inc.¸³¨Æ
2.CMC Pharma Solutions Group Hong Kong Limited¸³¨Æ
3.PharmTak, Inc. ¸³¨Æªø
4.Curous Inc.¸³¨Æªø
5.¦¿Ä¬³Õëä¥Í§ÞÂåÀø¬ì§Þ¦³¤½¥q¸³¨Æªø
6.PlexBio Hongkong Co., Limited ¸³¨Æªø
7.àÈùÖ(ªÑ)¤½¥q¸³¨Æ
8.^Äݶ}°Ò¸s®q¤ôÄRªÚ(ªÑ)¤½¥q¥xÆW¤À¤½¥q¸³¨Æ
9.®Ðº³¥Íª«§Þ³N(ªÑ)¤½¥q¸³¨Æªø
10.µØÑԥͪ«¬ì§Þ(ªÑ)¤½¥q¸³¨Æ
Carolyn Tsao¥Ø«eÝ¥ô:Curous Inc.,¸³¨Æ
Stuart Michael Palmer¥Ø«eÝ¥ô:
1.Principal Consultant of BioConsulting International, LLC.
2.Principal Consultant of Halteres Associates, LLC.
¤j¾ô«O§»¥Ø«eÝ¥ô:
1.General Manager of Advanced Diagnostics Business Development Department,
Life Innovation of Denka Company Limited.
2.Officer Performing Duties of Denka Kew Genomics.
±ä¼w·:¥Ø«eÝ¥ô
1. ¨Î®æ¹«~(ªÑ)¤½¥q¸³¨Æªø
2. ¨Î¨Å¹«~(ªÑ)¤½¥q¸³¨Æªø
3. ¼w®õ¬ì§Þ(ªÑ)¤½¥q¸³¨Æªø
4. ³Ü¦n¤ô(ªÑ)¤½¥q¸³¨Æ
5. Accession Limited¸³¨Æ
6. »E¹©¬ì§Þ(ªÑ)¤½¥qªk¤H¥Nªí¤H¸³¨Æ
7. ¨Î«°¹ê·~(ªÑ)¤½¥q¸³¨Æ
8. ¨Îª¿¹q¤l(ªÑ)¤½¥qºÊ¹î¤H
9. Standard Investment (Cayman)Limited¸³¨Æ
10. ¨Î®æ(»´ä)(ªÑ)¤½¥q¸³¨Æ
11. ¨Î®æ§ë¸ê(¤¤°ê)¦³¤½¥q¸³¨Æ
12. ¨N¼w§ë¸êªÑ¥÷¦³¤½¥q¸³¨Æªø
13. ¨Î¤¹§ë¸êªÑ¥÷¦³¤½¥q¸³¨Æ
14. ¨Î±¶§ë¸êªÑ¥÷¦³¤½¥q¸³¨Æ
§E°ê¨}:¥Ø«eÝ¥ô
1.¦¿Ä¬¯þ«H¥Íª«§Þ³N¦³¤½¥q¸³¨Æªø
2.ªC¦{¶q±d¬ì§Þ¦³¤½¥q¸³¨Æªø
3.Apollomics Inc.¥þ²yº®u°õ¦æ©x
4.SISCAPA Assay Technologies Inc¸³¨Æ
5.QuanDx Inc¸³¨Æ
6.Nvigen, Inc¸³¨Æ
7.Oranoxis Inc¸³¨Æ
8.¤j³sÂ娦¬ì§Þ¦³¤½¥q¸³¨Æ
9.Applied Stemcell Inc. Chairman of the board
10.Immune-Onc Inc.¸³¨Æ
11.«n¨Ê¤TÅ|¬öÂåÃĬì§Þ¦³¤½¥q¸³¨Æ
12.®ý¦¿°··sì¤O¨îÃĦ³¤½¥q¸³¨Æªø
13.µØÁp¥Íª«¬ì§ÞªÑ¥÷¦³¤½¥q¸³¨Æ
14.Alpine Biosciences, Inc.¸³¨Æ
4.³\¥i±q¨ÆÄv·~¦æ¬°¤§´Á¶¡:¾á¥ô¸³¨Æ´Á¶¡
5.¨Mij±¡§Î¡]½Ð¨Ì¤½¥qªk²Ä209±ø»¡©úªí¨Mµ²ªG¡^:¸g¥X®uªÑªF§ë²¼ªí¨M·Ó®×³q¹L
6.©Ò³\¥i¤§Äv·~¦æ¬°¦pÄݤj³°¦a°Ï¨Æ·~¤§Àç·~ªÌ¡A¸³¨Æ©m¦W¤Î¾ºÙ¡]«DÄݤj³°¦a°Ï¨Æ·~¤§
Àç·~ªÌ¡A¥H¤UÄæ¦ì½Ð¿é¤£¾A¥Î¡^:
1.¸³¨Æ:±ä¥Å
2.¿W¥ß¸³¨Æ:§E°ê¨}
7.©Ò¾á¥ô¸Ó¤j³°¦a°Ï¨Æ·~¤§¤½¥q¦WºÙ¤Î¾°È:
±ä¥Å:¦¿Ä¬³Õëä¥Í§ÞÂåÀø¬ì§Þ¦³¤½¥q¸³¨Æªø
§E°ê¨}
1.¦¿Ä¬¯þ«H¥Íª«§Þ³N(ªÑ)¤½¥q¸³¨Æªø
2.ªC¦{¶q±d¬ì§Þ¦³¤½¥q¸³¨Æªø
3.¤j³sÂ娦¬ì§Þ¦³¤½¥q¸³¨Æ
4.«n¨Ê¤TÅ|¬öÂåÃĬì§Þ¦³¤½¥q¸³¨Æ
8.©Ò¾á¥ô¸Ó¤j³°¦a°Ï¨Æ·~¦a§}:
1.¦¿Ä¬³Õëä¥Í§ÞÂåÀø¬ì§Þ¦³¤½¥q:±`¦{¥«ªZ¶i°Ï±`¦{¦è¤Ó´ò¬ì§Þ²£·~¶éªø´¸ô9¸¹C2®y
2.¦¿Ä¬¯þ«H¥Íª«§Þ³N(ªÑ)¤½¥q:¦¿Ä¬¬Ù®õ¦{°ê®aÂåÃݪ·s§Þ³N²£·~¶}µo°Ï§öªL¸ô28¸¹
3.ªC¦{¶q±d¬ì§Þ¦³¤½¥q:ªC¦{¥«Àئ¿°ÏÀئw¸ô688¸¹¤Ñ©M°ª¬ìD®y4¼h
4.¤j³sÂ娦¬ì§Þ¦³¤½¥q:¿ñ¹ç¬Ù¤j³s¸gÀÙ§Þ³N¶}µo°Ï¿ñªeªF¸ô9¸¹
5.«n¨Ê¤TÅ|¬öÂåÃĬì§Þ¦³¤½¥q:«n¨Êµµª÷(¦¿¹ç)¬ì§Þ³Ð·~¯S§OªÀ°Ï
6.®ý¦¿°··sì¤O¨îÃĦ³¤½¥q:®ý¦¿¬ÙªC¦{¥«¿½¤s°ÏªC¦{ªÅ´ä¸gÀÙ°Ï«Oµ|¸ô¦è°¼«Oµ|¤j·H
836«Ç
9.©Ò¾á¥ô¸Ó¤j³°¦a°Ï¨Æ·~Àç·~¶µ¥Ø:¥Í§ÞÂåÀø¡B·sÃĬãµo¡BÀç¾i°·±d¿Ô¸ß¡BÂåÀø¾¹±ñ¡C
10.¹ï¥»¤½¥q°]°È·~°È¤§¼vÅTµ{«×:µL
11.¸³¨Æ¦p¦³¹ï¸Ó¤j³°¦a°Ï¨Æ·~±q¨Æ§ë¸êªÌ¡A¨ä§ë¸êª÷ÃB¤Î«ùªÑ¤ñ¨Ò:¤£¾A¥Î
12.¨ä¥LÀ³±Ô©ú¨Æ¶µ:µL
<ºK¿ý¤½¶}¸ê°TÆ[´ú¯¸>
¿³Âd¥¿±`¥æ©ö¤¤

ªÑªF·|°T®§
³Ìªñ¤@´ÁªÑªF±`·|¤w©ó 114/06/19 µ²§ô

ªÑªFÅv®§³qª¾
106¦~¿ì²z²{¼W¡A¨C±i¥i»{331.802709 ªÑªÑ¡A»{ÁÊ»ù 20 ¤¸¤¸
105¦~¿ì²z´«²¼¡A´«ªÑ¤ñ²v: 0.00